Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2015 Jul 11;21(10):1739–1745. doi: 10.1016/j.bbmt.2015.07.004

Figure 3. Prognostic biomarkers prior the clinical signs of SOS in the independent cohort.

Figure 3

Plasma biomarker concentrations measured by ELISA in patients with SOS (SOS+) and without SOS (SOS−) at different days post-HCT (−7, 0, +7, +14). The data are shown as mean ± standard error of the mean (SEM). Median differences assessed with Wilcoxon rank sum test, significant at p < 0.05. The numbers beneath the SOS categories are the AUC percentages for each marker and days post-HCT when significant.